Third Pole Therapeutics is a Waltham, MA-based company developing transformative cardio-pulmonary therapies. We are building on our team’s pioneering legacy in inhaled nitric oxide (iNO) therapy, the current standard of care to treat hypoxic respiratory failure in newborns, to develop next-generation, life-saving heart and lung therapies. Our hospital and home-based platforms are being designed to be user friendly, economical, lightweight and highly accurate.
Capable of generating nitric oxide from air and electricity on-demand and on-site, Third Pole platforms eliminate the need for large compressed gas cylinders. We believe our novel approach of delivering electrically generated nitric oxide (eNO) on demand in both the hospital and home settings has the potential to provide clinicians with flexible and innovative solutions in therapeutic fields beyond hypoxic respiratory failure, including pulmonary hypertension, interstitial lung disease, chronic obstructive pulmonary disease, cystic fibrosis, and critical viral and bacterial infectious disease management.
In addition to applying its core technology to multiple therapeutic applications, the Company is forging high impact strategic partnerships to expedite the global launch of iNO therapy delivery systems to patients in multiple settings outside the hospital.
Third Pole’s elite team of engineers, technicians and scientists have harnessed and advanced the technology created by Massachusetts General Hospital, the global center of excellence for research in the biological roles of nitric oxide, to uniquely deliver safe, simple and accurate iNO therapies wherever they are needed.
Third Pole is not providing any medical advice through this website.